Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine

Adverse Drug Reactions and Toxicological Reviews

Volumn 19, Issue 4, 2000, Pages 293-312

  Gardiner, S J ^a   Begg, E J ^a   Barclay, M L ^a   Kirkpatrick, C M J ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; 6 THIOURIC ACID; ALLOPURINOL; AZATHIOPRINE; BALSALAZIDE; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FUROSEMIDE; GLUTATHIONE TRANSFERASE; GUANINE NUCLEOTIDE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MERCAPTOPURINE; METHOTREXATE; OLSALAZINE; SALAZOSULFAPYRIDINE; SALICYLIC ACID; SALICYLIC ACID DERIVATIVE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; XANTHINE OXIDASE;

BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTE; GASTROINTESTINAL DISEASE; GENETIC POLYMORPHISM; GENOTYPE; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY REACTION; KIDNEY GRAFT REJECTION; LESCH NYHAN SYNDROME; LIVER TOXICITY; PANCREATITIS; PHARMACOLOGICAL BLOCKING; RACE DIFFERENCE; RHEUMATIC DISEASE; SEX DIFFERENCE; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ANIMALS; AZATHIOPRINE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 0034510578     PISSN: 0964198X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (107)

1. Kidney transplantation in modified recipients
2. Azathioprine and 6-mercaptopurine in Crohns disease: A meta-analysis
3. Azathioprine in rheumatoid arthritis - A double blind cross-over study
4. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: Favorable response to prednisone and azathioprine
5. Psoriasis and bullous pemphigoid treated with azathioprine
6. The pharmacology of orally administered chemotherapy: A reappraisal
7. Further experience with azathioprine in rheumatoid arthritis
8. Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis - A twenty-four-week controlled clinical trial
9. Thiopurine methyltransferase genotype predicts the therapy-limiting severe toxicity from azathioprine
10. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis
11. Biochemistry and pharmacology of purine analogues
12. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine
13. The purine path to chemotherapy
14. Azathioprine metabolism: Pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients
15. Metabolism of thiopyrimidines and thiopurines: S-methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues
16. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia
17. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity
18. Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations
19. Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population
20. Thiopurine methyltransferase activity in American white subjects and black subjects
21. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
22. Human liver xanthine oxidase: Nature and extent of individual variation
23. Effect of allopurinol on pharmacokinetics of 6-mercaptopurine (NSC755) in cancer patients
24. The effects of azathioprine (Imuran) on purine synthesis in clinical disorders of purine metabolism
25. Variable bioavailability of oral mercaptopurine - Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered
26. Large interindividual variability in bioavailability of azathioprine in renal transplant recipients
27. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration
28. Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia
29. Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment
30. 6-Mercaptopurine: Apparent lack of relation between prescribed dose and biological effect in children with leukaemia
31. 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia
32. Childhood leukaemia: A relationship between intracellular 6-mercaptopurine metabolites and neutropenia
33. Thiopurine drugs in the treatment of childhood leukaemia: The influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity
34. Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia
35. Pancytopenia related to azathioprine: An enzyme deficiency caused by a common genetic polymorphism: A review
36. Azathioprine pharmacogenetics: The relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation
37. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine?
38. Azathioprine metabolism in kidney transplant recipients
39. Monitoring of azathioprine treatment by determination of 6-thioguanine nucleotide concentrations in erythrocytes
40. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia
41. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation
42. Possibilities for therapeutic drug monitoring of azathioprine: 6-Thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells
43. Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine
44. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia
45. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease
46. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease
47. An intravenous loading dose of azathioprine decreases time to response in patients with Crohn's disease
48. Thiopurine methyltransferase biochemical genetics: Human lymphocyte activity
49. Pharmacogenetics of human thiopurine methyltransferase: Kidney-erythrocyte correlation and immunotitration studies
50. Human liver thiopurine methyltransferase pharmacogenetics: Biochemical properties, liver-erythrocyte correlation and presence of isozymes
51. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients
52. Intraindividual variability in red blood cell thiopurine methyltransferase activity
53. Thiol S-methylation in uremia: Erythrocyte enzyme activities and plasma inhibitors
54. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients
55. Azathioprine myelotoxicity related to elevated 6-thioguanine nucleotides in heart transplantation
56. Sulphasalazine inhibition of thiopurine methyltransferase: Possible mechanism for interaction with 6-mercaptopurine and azathioprine
57. Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction
58. Balsalazide and azathioprine or 6-mercaptopurine: Evidence for a potentially serious interaction
59. Inhibition of human thiopurine methyltransferase by urusemide, bendroflumethiazide and richlormethiazide
60. Identification of factors regulating thiopurine methyltransferase activity in a Norwegian population
61. Thiopurine methyltransferase activity in a French population: H.p.l.c. assay conditions and effects of drugs and inhibitors
62. Erythrocyte thiopurine methyltransferase activity in a Korean population
63. Thiopurine methyltransferase activity in a Korean population sample of children
64. Thiopurine methyltransferase activity in a sample population of black subjects in Florida
65. Thiopurine S-methyltransferase activity in a Chinese population
66. Interethnic differences in thiopurine methyltransferase activity
67. Importance of 6-mercaptopurine dose in lymphoblastic leukaemia
68. Childhood lymphoblastic leukaemia: Sex difference in 6-mercaptopurine utilization
69. Thiopurine methyltransferase pharmacogenetics: Human gene cloning and characterization of a common polymorphism
70. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase
71. Thiopurine S-methyltransferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians
72. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms
73. Human thiopurine methyltransferase pharmacogenetics - Kindred with a terminal exon splice junction mutation that results in loss of activity
74. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis
75. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans
76. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance
77. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population
78. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations
79. Thiopurine methyltransferase alleles in British and Ghanaian populations
80. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: A possible indicator of non-compliance?
81. Serial 6-mercaptopurine (6-MP) metabolite measurements in combination with dose escalation unmasks an important biochemical explanation for "6-MP resistance"
82. Immunosuppressive therapy: The relationship between clinical response and immunologic competence
83. Azathioprine: An update on clinical efficacy and safety in inflammatory bowel disease
84. 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity
85. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience
86. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia
87. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-Mercaptopurine dosage strategies
88. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency
89. Prevention and management of the adverse effects associated with immunosuppressive therapy
90. Thiopurine methyltransferase pharmacogenetics: Alternative molecular diagnosis and preliminary data from Northern Portugal
91. Gastrointestinal side effects of azathioprine in patients with inflammatory bowel disease are not related to thiopurine methyltransferase polymorphism
92. Azathioprine hypersensitivity: Case report and review of the literature
93. Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis
94. Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine
95. Hypersensitivity reaction to azathioprine
96. Successful desensitization for azathioprine skin rash in a patient with severe Crohn's disease
97. Azathioprine toxicity in neuromuscular diseases
98. Hypersensitivity to azathioprine in myasthenia gravis
99. Early azathioprine intolerance in IBD patients is imidazole-related and independent of thiopurine methyltransferase (TPMT) activity
100. 6-Mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity
101. Risk of cancer in renal-transplant recipients
102. Collaborative United Kingdom - Australasian study of cancer in patients treated with immunosuppressive drugs
103. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment
104. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease
105. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis
106. Cause of death in rheumatoid arthritis
107. Thioguanine (6-TG): A therapeutic alternative in a subgroup of IBD patients failing 6-mercaptopurine (6-MP)